Revvity Stock: Is Wall Street Bullish or Bearish?

Revvity, Inc. (RVTY), a Massachusetts-based health sciences solutions provider, has demonstrated strong performance in the stock market. With a market capitalization of $13.9 billion, the company specializes in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and more.

Shares of RVTY have outperformed the broader market, gaining 39.1% over the past year compared to the S&P 500 Index's 20.5% rise. Furthermore, RVTY's stock rose 28.9% in 2026, surpassing the S&P 500's 12.1% increase on a year-to-date basis. Notably, RVTY has outperformed not only the S&P 500 but also the State Street Health Care Select Sector SPDR ETF (XLV), which gained 27.4% and 12.8% YTD, respectively.

The company's success can be attributed to its strong performance in diagnostics, driven by reproductive health, ex-China immunodiagnostics, newborn screening, and AI-driven demand. Additionally, RVTY exited its China immunodiagnostics business and reinvested tariff refunds into capacity and innovation. Analysts have a generally moderate outlook, with six "Strong Buy" ratings and eleven "Hold" ratings, resulting in a consensus of "Moderate Buy."

JPMorgan Chase & Co. analyst Casey Woodring maintains a "Hold" rating with a price target of $110, but the Street-high target of $145 indicates a potential 16.2% upside.